EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Lunsumio (mosunetuzumab) for follicular lymphoma with conditional approval and orphan medicine designation granted to Roche Registration GmbH…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Follicular. MAH: Roche Registration GmbH. Decision date: 17/11/2025. Conditional approval. Orphan medicine